Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
6.76
-0.43 (-5.98%)
At close: Apr 16, 2025, 4:00 PM
6.82
+0.06 (0.89%)
After-hours: Apr 17, 2025, 4:10 PM EDT
DAWN Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for DAWN stock have an average target of 32.29, with a low estimate of 25 and a high estimate of 40. The average target predicts an increase of 377.66% from the current stock price of 6.76.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DAWN stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 2 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +432.54% | Apr 3, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $39 → $27 | Strong Buy | Maintains | $39 → $27 | +299.41% | Mar 25, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $39 → $34 | Buy | Maintains | $39 → $34 | +402.96% | Mar 5, 2025 |
| Wedbush | Wedbush | Buy Reiterates $32 | Buy | Reiterates | $32 | +373.37% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $36 | Strong Buy | Maintains | $40 → $36 | +432.54% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
164.98M
from 131.16M
Increased by 25.78%
Revenue Next Year
277.78M
from 164.98M
Increased by 68.37%
EPS This Year
-1.41
from -1.02
EPS Next Year
-0.73
from -1.41
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 196.5M | 341.3M | 519.0M | ||
| Avg | 165.0M | 277.8M | 433.5M | ||
| Low | 132.8M | 199.2M | 323.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 49.8% | 106.8% | 86.8% | ||
| Avg | 25.8% | 68.4% | 56.1% | ||
| Low | 1.2% | 20.8% | 16.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.79 | -0.11 | 0.79 | ||
| Avg | -1.41 | -0.73 | 0.47 | ||
| Low | -2.70 | -2.61 | 0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.